Clinical trial · Observational
Use of Axillary Ultrasound to Guide Breast Cancer Management in the Genomic Assay Era
Use of Axillary Ultrasound to Guide Breast Cancer Management in the Genomic Assay Era: A Retrospective Cohort Study
NCT06038110CI-TRIAL-00069605unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators aimed to determine if axillary ultrasound can reliably distinguish between patients with limited or high nodal burden, so that the patients with limited nodal burden can potentially avoid chemotherapy and instead receive upfront surgery followed by gene assay testing.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Axillary Ultrasound | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| axillary ultrasound | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- the number of abnormal nodes on ultrasound
- timeFrame
- from the date of diagnosis to the date of surgery, up to 12 weeks
- description
- the number of abnormal nodes on ultrasound which was done at the time of diagnosis will be measured
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * breast cancer patients with T1-3, HR-positive and HER2-negative disease. * aged≥ 50 years old * had axillary ultrasound prior to operation * axillary lymph node dissection Exclusion Criteria: * Patients with neoadjuvant chemotherapy * bilateral cancers
References
Publications (0)
Data not yet available
No reference posted for this study.